Research graph
References from Survival Impact of Bevacizumab According to Chemotherapy Response Score in Advanced High-Grade Serous Ovarian Carcinoma Treated with Neoadjuvant Chemotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries
10.3322/caac.70090 · 2026 · External reference
Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review
10.1016/j.ctrv.2025.102945 · 2025 · External reference
Ovarian Cancer: A Review
10.1001/jama.2025.9495 · 2025 · External reference
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
10.1200/jco-24-02589 · 2025 · External reference
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
10.1056/nejmoa0908806 · 2010 · External reference
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial
10.1016/s0140-6736(14)62223-6 · 2015 · External reference
Utilization of Primary Cytoreductive Surgery for Advanced-Stage Ovarian Cancer
10.1001/jamanetworkopen.2024.39893 · 2024 · External reference
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma
10.1200/jco.2014.60.5212 · 2015 · External reference
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
10.1016/j.ygyno.2019.04.679 · 2019 · External reference
10.3390/jcm12062155
10.3390/jcm12062155 · External reference
Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC)
10.1016/j.ygyno.2025.01.012 · 2025 · External reference
Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy
10.3802/jgo.2024.35.e73 · 2024 · External reference
A phase 3 trial of bevacizumab in ovarian cancer
10.1056/nejmoa1103799 · 2011 · External reference
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: A randomised, open-label, phase 3 trial
10.1016/s1470-2045(20)30142-x · 2020 · External reference
Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review
10.3390/curroncol30090592 · 2023 · External reference
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
10.1200/jco.2013.51.4489 · 2014 · External reference
10.3390/cancers16223801
10.3390/cancers16223801 · External reference
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial
10.1016/s1470-2045(15)00086-8 · 2015 · External reference
Identification of Patients with Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
10.1200/jco.22.01207 · 2022 · External reference
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial
10.1016/s1470-2045(17)30279-6 · 2017 · External reference
The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: A meta-analysis
10.1080/14796694.2025.2548188 · 2025 · External reference
10.3389/fphar.2025.1566604
10.3389/fphar.2025.1566604 · External reference
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
10.1016/j.ygyno.2015.08.004 · 2015 · External reference
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: A randomised, phase 3 trial
10.1016/s1470-2045(20)30637-9 · 2021 · External reference
Ovarian Cancer: A Review
10.1001/jama.2025.9495 · ExternalCitation · doi-reference
Utilization of Primary Cytoreductive Surgery for Advanced-Stage Ovarian Cancer
10.1001/jamanetworkopen.2024.39893 · ExternalCitation · doi-reference
Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review
10.1016/j.ctrv.2025.102945 · ExternalCitation · doi-reference
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
10.1016/j.ygyno.2015.08.004 · ExternalCitation · doi-reference
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
10.1016/j.ygyno.2019.04.679 · ExternalCitation · doi-reference
Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC)
10.1016/j.ygyno.2025.01.012 · ExternalCitation · doi-reference
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial
10.1016/s0140-6736(14)62223-6 · ExternalCitation · doi-reference
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial
10.1016/s1470-2045(15)00086-8 · ExternalCitation · doi-reference
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial
10.1016/s1470-2045(17)30279-6 · ExternalCitation · doi-reference
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: A randomised, open-label, phase 3 trial
10.1016/s1470-2045(20)30142-x · ExternalCitation · doi-reference
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: A randomised, phase 3 trial
10.1016/s1470-2045(20)30637-9 · ExternalCitation · doi-reference
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
10.1056/nejmoa0908806 · ExternalCitation · doi-reference
A phase 3 trial of bevacizumab in ovarian cancer
10.1056/nejmoa1103799 · ExternalCitation · doi-reference
The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: A meta-analysis
10.1080/14796694.2025.2548188 · ExternalCitation · doi-reference
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
10.1200/jco-24-02589 · ExternalCitation · doi-reference
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
10.1200/jco.2013.51.4489 · ExternalCitation · doi-reference
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma
10.1200/jco.2014.60.5212 · ExternalCitation · doi-reference
Identification of Patients with Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
10.1200/jco.22.01207 · ExternalCitation · doi-reference
Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries
10.3322/caac.70090 · ExternalCitation · doi-reference
10.3389/fphar.2025.1566604
10.3389/fphar.2025.1566604 · ExternalCitation · doi-reference
10.3390/cancers16223801
10.3390/cancers16223801 · ExternalCitation · doi-reference
Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review
10.3390/curroncol30090592 · ExternalCitation · doi-reference
10.3390/jcm12062155
10.3390/jcm12062155 · ExternalCitation · doi-reference
Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy
10.3802/jgo.2024.35.e73 · ExternalCitation · doi-reference
